Serina Therapeutics FY2025 net loss widens 71.46% to $(19.2) million; revenue rises more than doubled to $130,000

Reuters03-26
Serina <a href="https://laohu8.com/S/LENZ">Therapeutics</a> FY2025 net loss widens 71.46% to $(19.2) million; revenue rises more than doubled to $130,000
  • Serina published its annual report on Form 10-K, reporting a net loss of USD 19.2 million and grant revenues of USD 130,000.
  • Research and development expense rose 75.9% to USD 13.2 million, driven mainly by higher clinical activities, increased headcount-related compensation, and higher consultant and outsourced research spend.
  • General and administrative expense increased 14.3% to USD 11.0 million, primarily due to higher stock-based compensation, public company infrastructure consulting, and investor outreach, partly offset by lower legal and certain professional fees.
  • Cash and cash equivalents were USD 3.1 million, and net cash used in operating activities was USD 18.0 million.
  • Management said conditions raise substantial doubt about continuing as a going concern and that existing cash is not expected to fund operations for at least 12 months from the financial statements’ issuance date.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Serina Therapeutics Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001708599-26-000016), on March 25, 2026, and is solely responsible for the information contained therein.

At the request of the copyright holder, you need to log in to view this content

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap
Leave a comment